• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

    5/1/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email

    WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant ("CA") use is associated with better management of congestive heart failure ("CHF"). The analysis, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care," details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PCP that uses Counterpart Assistant.

    Key highlights of the study include:

    • A relationship with a CA provider was associated with better outcomes, including a lower average number of all-cause hospitalizations (18% lower) and 30-day readmissions (25% lower) for CHF patients enrolled in Clover Health's Medicare Advantage (MA) plans.
    • CA provides actionable insights at the point of care, which supports earlier detection of chronic disease, tracking of disease progression and severity, and guideline-based treatment.
    • A relationship with a PCP who uses CA was associated with better clinical care for patients with CHF, including higher rates of outpatient cardiologist visits and in-home care management.

    "At Counterpart Health, we are committed to developing technology solutions that truly augment the capabilities of our healthcare providers," stated Dr. David Tsay MD, PhD, Chief Medical Officer of Counterpart Health and co-author of the whitepaper. "The results of this study on Counterpart Assistant and congestive heart failure demonstrate how providing clinicians with timely, data-driven insights can help lead to significant improvements in patient outcomes. This technology is designed to be a collaborative partner, empowering them to deliver even more effective and personalized care."

    CA has empowered providers in patient care by focusing on clinical excellence in chronic disease detection and management, emphasizing proactive interventions and longitudinal care. Congestive heart failure in particular is a prevalent and potentially debilitating chronic condition that poses a substantial burden on patients in the Medicare population. According to CMS, heart failure is the leading cause of hospitalizations among older adults, and Medicare enrollees with heart failure have the highest readmission rate of any condition.

    "For value-based care to truly succeed, we must prioritize proactive and effective management of chronic diseases," said Conrad Wai, CEO of Counterpart Health. "Counterpart Assistant is a testament to this commitment, offering clinicians actionable intelligence that can translate to improved care for patients with heart failure and a significant decrease in costly acute episodes. This technology demonstrates that enhanced clinical quality and reduced cost of care delivery are not mutually exclusive, but rather, achievable through intelligent physician enablement."

    This is the fourth retrospective data analysis conducted by the Company to measure the clinical impact of CA on the identification and management of chronic diseases. The previous analyses focus on the earlier diagnosis and treatment of Diabetes and Chronic Kidney Disease, and the technology's impact on Medication Adherence.

    To learn more about Counterpart Health, visit: www.counterparthealth.com.

    About Counterpart Health

    Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI powered physician enablement platform. Counterpart Health's flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health's Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology's impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

    Investor Relations:

    Ryan Schmidt

    [email protected]

    Press Inquiries:

    [email protected]



    Primary Logo

    Get the next $CLOV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    SEC Filings

    See more
    • SEC Form 144 filed by Clover Health Investments Corp.

      144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      6/17/25 4:21:44 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      6/12/25 4:27:22 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/14/25 8:59:21 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Clover Health with a new price target

      Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

      12/17/24 8:33:41 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • UBS initiated coverage on Clover Health with a new price target

      UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

      10/7/24 7:45:42 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SVB Leerink reiterated coverage on Clover Health Investments with a new price target

      SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

      2/25/22 5:03:33 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      8/13/24 4:06:53 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Director Garipalli Vivek bought $1,000,426 worth of shares (877,567 units at $1.14) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/20/24 4:03:32 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Loengard Anna U bought $25,672 worth of shares (27,085 units at $0.95) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/20/24 6:57:29 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clover Health Set to Join Russell 3000® Index

      WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, also results in automatic membership in the large-cap Russell 1000® Index or small-cap Russell 2000® Index along with the relevant growth and value style indexes. FTSE Russe

      6/30/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare is quickly evolving into a digital-first operation, where top executives in the sector are doubling down on artificial intelligence, automation and analytics to reduce costs and improve billing accuracy. This is according to results of a survey from Everest Group (and supported by Omega Healthcare), which showed 85% of senior healthcare executives believe AI will improve efficiencies over the next five years. Now that multitasking AI Agents are being referred to as hospitals' newest "employees", AI-powered electronic noses are detecting scents for health and enviro

      5/6/25 9:45:00 AM ET
      $AMZN
      $CLOV
      $TDOC
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Toy Andrew covered exercise/tax liability with 308,950 shares, decreasing direct ownership by 3% to 10,560,047 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      7/3/25 4:21:39 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • CEO, Medicare Advantage Reynoso Jamie L. was granted 217,523 shares and covered exercise/tax liability with 85,596 shares, increasing direct ownership by 4% to 3,328,328 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      7/2/25 4:47:50 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • CEO, Medicare Advantage Reynoso Jamie L. sold $58,487 worth of shares (20,450 units at $2.86), decreasing direct ownership by 0.64% to 3,196,401 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/18/25 5:26:15 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Clover Health Set to Join Russell 3000® Index

      WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, also results in automatic membership in the large-cap Russell 1000® Index or small-cap Russell 2000® Index along with the relevant growth and value style indexes. FTSE Russe

      6/30/25 8:30:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage

      WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc

      4/7/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

      FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

      10/8/24 6:15:00 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Financials

    Live finance-specific insights

    See more
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025

      WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health's First Quarter 2025 Earnings Conference CallWhen: Tuesday, May 6, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or

      4/8/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

      Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between

      2/27/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/12/24 2:31:31 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/4/24 11:25:56 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      7/7/23 4:35:52 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

      The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

      6/20/24 6:36:05 PM ET
      $CLOV
      Medical Specialities
      Health Care